Now showing items 1-1 of 1
The impact of cost sharing on adherence to ibrutinib for patients with diffuse large B-cell lymphoma
Purpose: Nonadherence with ibrutinib, an oral treatment for diffuse large B-cell lymphoma (DLBCL), has been associated with disease progression. We examined the relationship between out-of-pocket (OOP) ibrutinib costs and adherence to ibrutinib among new users with DLBCL. Patients and Methods: We conducted a retrospective ...